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The increased use of nephron-sparing surgery to treat localized renal cell carcinoma (RCC) lends weight to the
question of the value of microscopically positive surgical margins (PSM) in cases with a tumor bed macroscopically
free of residual tumor. The aim of this article is to highlight the data available on risk factors for PSM, their clinical
relevance, and possible therapeutic consequences. For this purpose, publications on the incidence and relevance of
PSM after partial nephrectomy from the last 15 years were examined and evaluated. We summarize that PSM are
generally rare, regardless of the surgical procedure, and are seen more often in connection with an imperative
indication for nephron-sparing surgery as well as a central tumor location. Most studies describe that PSM lead to a
moderate increase in the rate of local relapses, but no study has thus far been able to demonstrate an association
with shorter tumor-specific overall survival. Intraoperative frozen section analysis had no positive influence on the
risk of definite PSM in most trials. Therefore, we conclude that PSM should definitely be avoided. However, in
cases with a macroscopically tumor-free intraoperative resection bed, they should lead to close surveillance of the
affected kidney and not to immediate (re)intervention.
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In recent years, organ-sparing surgery for renal tumors
in terms of partial nephrectomy or tumor enucleation
has replaced radical nephrectomy as the standard pro-
cedure for treating locally confined renal cell carcinoma
(RCC) [1-8]. This change of therapy is based primarily
on findings indicating that organ-sparing surgery offers
the potential for better preservation of renal function
and a lower risk of cardiovascular sequelae [9-15]. Onco-
logical outcomes appear to be equivalent [3,16-20], and
perioperative morbidity seems to be only minimally higher
for nephron-sparing interventions [3,21,22]. Just like rad-
ical nephrectomy, partial nephrectomy should always aim
at complete tumor resection. The width of the normal tis-
sue margin or safety margin around the tumor appears to
be of no relevance here [1,23,24], but the increased fre-
quency of partial nephrectomies and tumor enucleations
has shown that a limited percentage of surgical specimens
(between 0 and 7%) have tumor cells in the margin* Correspondence: Julie@steinestel.com
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unless otherwise stated.(positive surgical margins, PSM) in the final histopatho-
logic evaluation (Figure 1) [25-27].
However, no prospective and/or randomized study has
yet been performed to investigate the prognostic signifi-
cance of histopathologically positive but intraoperative
macroscopically tumor-free surgical margins in predict-
ing the risk of local relapse, metachronous metastases,
and tumor-specific survival; only one nonsystematic re-
view has been published thus far [25]. Moreover, most
studies had a follow-up of less than five years. This article
gives a brief review of currently available data on risk fac-
tors for PSM and their potential clinical relevance.Review
Risk factors for positive surgical margins: surgical
technique
According to various studies, the incidence of PSM at final
pathology is between 0 and 7% for open surgery [28-37], 1
to 4% for laparoscopic interventions [32-34,38-46], and 4
to 6% [47-49] for robot-assisted surgery. Thus, with ap-
propriate experience and careful patient selection with re-
spect to the optimal surgical approach, PSM rates do notral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Representative microphotographs of positive surgical margin (PSM) in final histopathologic examination. A, overview shows
densely packed papillary and tubular structures closely approaching the inked surgical margin (arrows). B, higher magnification of the
marked region in A confirms neoplastic tubules reaching the inked surgical margin. Staining: hematoxylin-eosin; scale bar in A: 500 μm;
scale bar in B: 100 μm.
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[32-34,38,49,50].
Data from smaller studies suggest that enucleation
along the plane of the tumor pseudocapsule may be su-
perior to classic partial nephrectomy with regard to
the incidence of PSM. Verze et al. [51] retrospectively
compared pathological results in cT1 RCC patients
after partial nephrectomy (n = 309) and tumor enucle-
ation (n = 226). PSM rates were 6.7% and 1.3% (P =
0.01). Multivariate analysis also revealed a nearly five
times higher risk of PSM after classic partial nephrec-
tomy (P = 0.04). Minervini et al. [52] compared patho-
logical results as well as oncological outcomes in RCC
patients after partial nephrectomy (n = 982) and tumor
enucleation (n = 537) at 16 medical centers. With a
median follow-up of approximately four and a half
years, the five-year progression-free survival (88.9 ver-
sus 91.4%) and tumor-specific survival (93.9 versus
94.3%) did not differ significantly between the two
groups, although here too the PSM rate was higher
after classic partial nephrectomy (3.4 versus 0.2%).
Indication
Patients with an imperative indication for nephron-
sparing surgery (such as preexisting renal insuffi-
ciency, or a functional or anatomical single kidney)
have a higher incidence of larger and more unfavorably
located tumors than the total patient population. This
explains why an imperative indication could be identi-
fied as a risk factor for PSM in nearly all studies, at
least by univariate analysis. PSM rates of 9 to 28% are
described here [5,53-55]. Using multivariate analysis,
Bensalah et al. [56] also identified an imperative indi-
cation (in addition to tumor location) as an indepen-
dent risk factor for PSM at final pathology (hazard
ratio (HR) 14.3, 95% confidence interval (CI) 1.6 to
21.2; P = 0.02).Tumor-specific risk factors
According to a study by Kwon et al. [29] in 770 patients
who underwent open surgery, the PSM rate appears to be
unrelated to the histopathological subtype and possibly
also the differentiation of RCC. PSM were seen in 33 out
of 423 (8%) of all patients with tumors of high malignant
potential, and in 24 out of 347 (7%) patients with well-
differentiated tumors. In contrast to these findings, Bensa-
lah et al. [56] reported a higher incidence of PSM in pa-
tients with poorly differentiated carcinomas.
It is still controversial whether tumor size has an im-
pact on the PSM rate. While various research groups
were unable to demonstrate a correlation [28,43], others
found higher PSM rates mainly in smaller RCC [57,58].
Using uni- and multivariate analysis, Yossepowitch et al.
[57], for example, showed that small tumors are associ-
ated more often with PSM but less often with local re-
lapses. It can only be speculated why PSM have been
found more often in smaller renal tumors. Possible ex-
planations include the more frequent lack of a pseudo-
capsule as well as technical inadvertencies during surgical
resection or specimen preparation [25]. On the other
hand, according to Peycelon et al. [5] the PSM rate in very
large tumors (more than 7 cm) seems to be rising again.
Ani et al. [59] have also recently published a study show-
ing a higher PSM rate in patients with larger tumors or a
more advanced pathological stage.
It cannot yet be conclusively clarified whether tumor
location within the kidney can influence the PSM rate,
since none of the published studies included a reprodu-
cible nephrometry scoring system. However, available
data suggest that PSM is observed more frequently after
resection of centrally located tumors [46,56]. Bensalah et
al. [56] evaluated 111 patients with and 664 patients
without PSM and found positive margins in 26% of all
centrally located tumors, but only in 9.1% of all periph-
erally located tumors (P < 0.001).
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Intraoperative frozen section analysis (FSA) to ensure
tumor-free surgical margins is performed frequently and
may reduce the rate of PSM, at least in some patient
subgroups in laparoscopic surgery (clear cell/papillary
subtypes, upper/mid-pole tumors, exophytic/endophytic
tumors, pT1a/pT1 tumors, and tumors with histologic
differentiation (Fuhrman) grades 1 to 2 and 2 tumors)
[60]. However, in the same study, it has also been shown
that there is no impact of FSA on patient outcomes ex-
cept an improved recurrence-free survival in patients
with pT1 or exophytic renal cell carcinoma upon laparo-
scopic surgery, and no effect on tumor recurrence after
open surgery. Accordingly, several other studies con-
firmed that in contrast to individual macroscopic assess-
ment of the tumor bed by the surgeon, intraoperative
FSA seems to contribute no decisive information and
fails to predict final margin status in cases with a macro-
scopically tumor-free resection bed [25,61-65]. Palermo
et al. proposed quick-staining cytology as an alternative
to FSA in a recent publication and showed a good level
of agreement with final histologic examination (κ = 0.751;
P <0.0001) [62].
Impact of positive surgical margins on local relapses and
tumor-specific survival
It has not yet been conclusively clarified whether PSM
increase the risk of local relapses after partial nephrec-
tomy, even though the majority of studies suggest that
this is probably the case [5,29,35,56,66]. An overview
of published survival analyses is provided in Table 1.Table 1 Published hazard ratios (HR) for positive surgical mar
Reference number Number of cases HR (recurrence)
[5] PSM: 22 Not reported
NSM: 100
[68] PSM: 14 Not reported
NSM: 1787
[67] PSM: 13 Not reported
NSM: 155
[59] PSM: 71 Not reported
NSM: 587
[66] PSM: 21 18.4 (95% CI: 2.27
NSM: 922
[57] PSM: 77 1 (95% CI: 0.23-4
NSM: 1313
[35] PSM: 12 11.5 (95% CI: 4.66
NSM: 768
[56] PSM: 101 Not significant
NSM: 102
CI, confidence interval; CSS, cancer-specific survival; HR, hazard ratio; NSM, negativeBernhard et al. [35] found 26 (3.2%) local relapses in a
group of 809 partially nephrectomized patients during
a median follow-up of 27 months. In the univariate
analysis, the following correlated with local relapse: ad-
vanced tumor stage (pT3a), a tumor size greater than
4 cm, imperative indication, bilateral tumors, poor dif-
ferentiation (Fuhrman histologic differentiation grade
of more than 2), and PSM. Bilateral tumors (HR 6.3),
tumor size greater than 4 cm (HR 4.6), and especially
PSM (HR 11.5) also proved to be independent predic-
tors of ipsilateral relapse. Khalifeh et al. [66] even de-
scribed an 18.4 times higher risk of tumor relapse in
943 patients with a PSM rate of 2.2% after robot-
assisted surgery. Kwon et al. [29] showed that, in their
patient population (n = 770 with 57 (7%) cases of
PSM), local relapses only occurred in PSM cases of
high-grade malignant tumors.
Bensalah et al. [56] evaluated 111 patients with PSM
from various medical centers and established a correl-
ation between PSM and tumor relapse. Time to progres-
sion was also shorter in the PSM group (21.4 versus
24.7 months). However, when performing a subsequent
matched-pair analysis (n = 101 patients with and n = 102
without PSM), the authors no longer found a significant
difference in relapse-free survival (P = 0.11) or tumor-
specific overall survival (P = 0.4). Using multivariate ana-
lysis, an imperative indication for partial renal resection
(HR 14.3; 95% CI 1.6 to 21.2) and a central tumor loca-
tion (HR 1.2; 95% CI 1.06 to 1.8) proved to be independ-
ent risk factors for tumor relapse, but not PSM at final
pathology [56].gins in nephron-sparing surgery
HR (OS) HR (CSS)
Not reported Not significant
Not reported 3.45 (95% CI: 1.79-6.67)
Not reported 2.08 (95% CI: 0.84-5.17)
1.1 (95% CI: 0.66-1.94) Not significant
-110.8) Not reported Not reported
.3) Not reported Not reported
-45.1) Not reported Not reported
Not significant Not significant
surgical margins; OS, overall survival; PSM, positive surgical margins.
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[57], 77 out of 1344 (5.7%) patients had PSM; the median
follow-up was 3.4 years. In that study too, the risk of local
relapse did not differ between patients with or without
PSM: five-year rates for freedom from local relapse were
98% and 97%, respectively (P = 0.97). Multivariate analysis
revealed that, unlike tumor size, PSM was not a risk factor
for local relapse (HR 1.0; 95% CI 0.23 to 4.3) or metachro-
nous metastases (HR 1.6; 95% CI 0.6 to 4.1).
A study by Marszalek et al. [33] with a median follow-
up of 70.7 months showed that, in contrast to tumor size
and differentiation, the factor PSM does not predict
RCC relapse or overall survival.
In a large study recently published by Ani et al. [59], 71
of 664 (10.7%) Canadian patients analyzed retrospectively
showed PSM (follow-up of 7.9 years). In that study, the
tumor-specific five-year survival rate was 90.9% for pa-
tients with PSM and 91.9% for those without PSM (P =
0.58). Multivariate analysis also failed to identify PSM sta-
tus as an independent predictor of cancer-specific survival
(HR 1.1; 95% CI 0.66 to 1.94). Thus, microscopic PSM
does not appear to significantly influence tumor-specific
survival [5,25,33,41,56,57,67]. It has to be noted that in
2002, Frank et al. reported a HR of 3.45 (95% CI: 1.79 to
6.67) for cancer-specific survival in patients with PSM;
however, one limitation of that study was the small num-
ber of PSM cases (n = 14) compared to total cohort size
(n = 1801) [68].
Conclusions
PSM should definitely be avoided even if a certain safety
margin is no longer required in nephron-sparing surgery
for renal tumors [25,35]. However, PSM are apparently
associated only with an\slightly increased risk of local re-
lapse [33] and are seen especially in RCC that are large
[5], poorly differentiated [29,56], and/or more centrally
located [25,56]. On the other hand, no definite impact
on tumor-specific overall survival has as yet been dem-
onstrated [5,25,33,41,56,57]. Moreover, a number of
studies have already shown that the renal remnant con-
tained a residual tumor in only 0 to 39% of patients with
PSM who underwent prophylactic secondary nephrectomy
[25,41,56,58,69,70]. Consequently, a surveillance strategy
rather than a reoperation (repeat resection, completion
nephrectomy, or a minimally invasive ablation tech-
nique) is now recommended for patients with PSM at
final pathology [25,69].
Abbreviations
CI: confidence interval; CSS: cancer-specific survival; FSA: frozen section
analysis; HR: hazard ratio; NSM: negative surgical margins; OS: overall survival;
PSM: positive surgical margins; RCC: renal cell carcinoma; (p)T: (pathological)
tumor stage.
Competing interests
The authors declare that they have no competing interests.Authors’ contributions
JS and AJS participated in the design of this review. JS, SS and AJS reviewed
literature on PSM risk factors, impact of PSM on local relapses and overall
survival. KS reviewed literature on pathologic PSM risk factors and the role of
intraoperative frozen section analysis. All authors read and approved the final
manuscript.
Author details
1Department of Urology, Münster University Medical Center,
Albert-Schweitzer-Campus 1, Building A1, 48149 Münster, Germany.
2Department of Urology, Hannover University Medical School,
Carl-Neubergstr. 1, 30625 Hannover, Germany. 3Department of Pathology,
Bundeswehrkrankenhaus Ulm, Oberer Eselsberg 40, 89081 Ulm, Germany.
Received: 18 March 2014 Accepted: 20 July 2014
Published: 8 August 2014
References
1. Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS,
Patard JJ, Mulders PF, Sinescu IC: EAU guidelines on renal cell carcinoma:
the 2010 update. Eur Urol 2010, 58:398–406.
2. Campbell SC, Novick AC, Belldegrun A, Blute ML, Chow GK, Derweesh IH,
Faraday MM, Kaouk JH, Leveillee RJ, Matin SF, Russo P, Uzzo RG: Guideline
for management of the clinical T1 renal mass. J Urol 2009, 182:1271–1279.
3. Minervini A, Serni S, Tuccio A, Siena G, Vittori G, Masieri L, Giancane S,
Lanciotti M, Khorrami S, Lapini A, Carini M: Simple enucleation versus
radical nephrectomy in the treatment of pT1a and pT1b renal cell
carcinoma. Ann Surg Oncol 2012, 19:694–700.
4. Coffin G, Hupertan V, Taksin L, Vaessen C, Chartier-Kastler E, Bitker MO,
Roupret M: Impact of elective versus imperative indications on oncologic
outcomes after open nephron-sparing surgery for the treatment of
sporadic renal cell carcinomas. Ann Surg Oncol 2011, 18:1151–1157.
5. Peycelon M, Hupertan V, Comperat E, Renard-Penna R, Vaessen C, Conort P,
Bitker MO, Chartier-Kastler E, Richard F, Roupret M: Long-term outcomes
after nephron sparing surgery for renal cell carcinoma larger than 4 cm.
J Urol 2009, 181:35–41.
6. Hansen J, Sun M, Bianchi M, Rink M, Tian Z, Hanna N, Meskawi M,
Schmitges J, Shariat SF, Chun FK, Perrotte P, Graefen M, Karakiewicz PI:
Assessment of cancer control outcomes in patients with high-risk renal
cell carcinoma treated with partial nephrectomy. Urology 2012, 80:347–353.
7. Becker F, Roos FC, Janssen M, Brenner W, Hampel C, Siemer S, Thuroff JW,
Stockle M: Short-term functional and oncologic outcomes of nephron-
sparing surgery for renal tumours >/=7 cm. Eur Urol 2011, 59:931–937.
8. Hegele A, Skrobek L, Schrader AJ: Update Urooncology: news with clinical
relevance from major scientific meetings 2013. Aktuelle Urol 2014, 45:21–32.
9. Huang WC, Levey AS, Serio AM, Snyder M, Vickers AJ, Raj GV, Scardino PT,
Russo P: Chronic kidney disease after nephrectomy in patients with renal
cortical tumours: a retrospective cohort study. Lancet Oncol 2006, 7:735–740.
10. Klarenbach S, Moore RB, Chapman DW, Dong J, Braam B: Adverse renal
outcomes in subjects undergoing nephrectomy for renal tumors: a
population-based analysis. Eur Urol 2011, 59:333–339.
11. Scosyrev E, Messing EM, Sylvester R, Campbell S, Van Poppel H: Renal
function after nephron-sparing surgery versus radical nephrectomy:
results from EORTC randomized trial 30904. Eur Urol 2014, 65:372–377.
12. Huang WC, Elkin EB, Levey AS, Jang TL, Russo P: Partial nephrectomy versus
radical nephrectomy in patients with small renal tumors–is there a
difference in mortality and cardiovascular outcomes? J Urol 2009, 181:55–61.
13. Thompson RH, Boorjian SA, Lohse CM, Leibovich BC, Kwon ED, Cheville JC,
Blute ML: Radical nephrectomy for pT1a renal masses may be associated
with decreased overall survival compared with partial nephrectomy.
J Urol 2008, 179:468–471.
14. Weight CJ, Lieser G, Larson BT, Gao T, Lane BR, Campbell SC, Gill IS, Novick
AC, Fergany AF: Partial nephrectomy is associated with improved overall
survival compared to radical nephrectomy in patients with
unanticipated benign renal tumours. Eur Urol 2010, 58:293–298.
15. MacLennan S, Imamura M, Lapitan MC, Omar MI, Lam TB, Hilvano-Cabungcal
AM, Royle P, Stewart F, MacLennan G, MacLennan SJ, Canfield SE, McClinton S,
Griffiths TR, Ljungberg B, N'Dow J, Ucan Systematic Review Reference Group, E.
A. U. Renal Cancer Guideline Panel: Systematic review of oncological out-
comes following surgical management of localised renal cancer. Eur Urol
2012, 61:972–993.
Steinestel et al. World Journal of Surgical Oncology 2014, 12:252 Page 5 of 6
http://www.wjso.com/content/12/1/25216. Van Poppel H, Da Pozzo L, Albrecht W, Matveev V, Bono A, Borkowski A,
Colombel M, Klotz L, Skinner E, Keane T, Marreaud S, Collette S, Sylvester
R: A prospective, randomised EORTC intergroup phase 3 study
comparing the oncologic outcome of elective nephron-sparing
surgery and radical nephrectomy for low-stage renal cell carcinoma.
Eur Urol 2011, 59:543–552.
17. Minervini A, Di Cristofano C, Lapini A, Marchi M, Lanzi F, Giubilei G, Tosi N,
Tuccio A, Mancini M, Della Rocca C, Serni S, Bevilacqua G, Carini M:
Histopathologic analysis of peritumoral pseudocapsule and surgical
margin status after tumor enucleation for renal cell carcinoma. Eur Urol
2009, 55:1410–1418.
18. Minervini A, Serni S, Tuccio A, Raspollini MR, Di Cristofano C, Siena G,
Vittori G, Saleh O, Lapini A, Carini M: Local recurrence after tumour
enucleation for renal cell carcinoma with no ablation of the tumour
bed: results of a prospective single-centre study. BJU Int 2011,
107:1394–1399.
19. Carini M, Minervini A, Masieri L, Lapini A, Serni S: Simple enucleation for
the treatment of PT1a renal cell carcinoma: our 20-year experience.
Eur Urol 2006, 50:1263–1268.
20. Steffens S, Junker K, Roos FC, Janssen M, Becker F, Henn D, Wegener G,
Siemer S, Hofmann R, Schrader M, Stockle M, Thuroff JW, Hartmann A,
Kuczyk MA, Schrader AJ, German Renal Tumor Network: Small renal cell
carcinomas - How dangerous are they really? Results of a large multicenter
study. Eur J Cancer 2014, 4:739–745.
21. Van Poppel H, Da Pozzo L, Albrecht W, Matveev V, Bono A, Borkowski A,
Marechal JM, Klotz L, Skinner E, Keane T, Claessens I, Sylvester R: A
prospective randomized EORTC intergroup phase 3 study comparing the
complications of elective nephron-sparing surgery and radical nephrectomy
for low-stage renal cell carcinoma. Eur Urol 2007, 51:1606–1615.
22. Schnoeller TJ, De Petriconi R, Hefty R, Jentzmik F, Waalkes S, Zengerling F,
Schrader M, Schrader AJ: Partial nephrectomy using porcine small
intestinal submucosa. World J Surg Oncol 2011, 9:1–5.
23. Sutherland SE, Resnick MI, Maclennan GT, Goldman HB: Does the size of
the surgical margin in partial nephrectomy for renal cell cancer really
matter? J Urol 2002, 167:61–64.
24. Castilla EA, Liou LS, Abrahams NA, Fergany A, Rybicki LA, Myles J, Novick AC:
Prognostic importance of resection margin width after nephron-sparing
surgery for renal cell carcinoma. Urology 2002, 60:993–997.
25. Marszalek M, Carini M, Chlosta P, Jeschke K, Kirkali Z, Knuchel R,
Madersbacher S, Patard JJ, Van Poppel H: Positive surgical margins after
nephron-sparing surgery. Eur Urol 2012, 61:757–763.
26. Borghesi M, Brunocilla E, Schiavina R, Martorana G: Positive surgical
margins after nephron-sparing surgery for renal cell carcinoma: incidence,
clinical impact, and management. Clin Genitourin Cancer 2013, 11:5–9.
27. Masson-Lecomte A, Yates DR, Bensalah K, Vaessen C, de la Taille A,
Roumiguie M, Doumerc N, Bruyere F, Soustelle L, Droupy S, Roupret M:
Robot-assisted laparoscopic nephron sparing surgery for tumors over
4 cm: operative results and preliminary oncologic outcomes from a
multicentre French study. Eur J Surg Oncol 2013, 39:799–803.
28. Patard JJ, Pantuck AJ, Crepel M, Lam JS, Bellec L, Albouy B, Lopes D,
Bernhard JC, Guille F, Lacroix B, De La Taille A, Salomon L, Pfister C, Soulie
M, Tostain J, Ferriere JM, Abbou CC, Colombel M, Belldegrun AS: Morbidity
and clinical outcome of nephron-sparing surgery in relation to tumour
size and indication. Eur Urol 2007, 52:148–154.
29. Kwon EO, Carver BS, Snyder ME, Russo P: Impact of positive surgical
margins in patients undergoing partial nephrectomy for renal cortical
tumours. BJU Int 2007, 99:286–289.
30. Zigeuner R, Quehenberger F, Pummer K, Petritsch P, Hubmer G: Long-term
results of nephron-sparing surgery for renal cell carcinoma in 114
patients: risk factors for progressive disease. BJU Int 2003, 92:567–571.
31. Lau WK, Blute ML, Weaver AL, Torres VE, Zincke H: Matched comparison of
radical nephrectomy vs nephron-sparing surgery in patients with unilat-
eral renal cell carcinoma and a normal contralateral kidney. Mayo Clinic
Proceedings 2000, 75:1236–1242.
32. Gill IS, Kavoussi LR, Lane BR, Blute ML, Babineau D, Colombo JR Jr, Frank I,
Permpongkosol S, Weight CJ, Kaouk JH, Kattan MW, Novick AC: Comparison
of 1,800 laparoscopic and open partial nephrectomies for single renal
tumors. J Urol 2007, 178:41–46.
33. Marszalek M, Meixl H, Polajnar M, Rauchenwald M, Jeschke K, Madersbacher
S: Laparoscopic and open partial nephrectomy: a matched-pair compari-
son of 200 patients. Eur Urol 2009, 55:1171–1178.34. Gong EM, Orvieto MA, Zorn KC, Lucioni A, Steinberg GD, Shalhav AL:
Comparison of laparoscopic and open partial nephrectomy in clinical
T1a renal tumors. J Endourol 2008, 22:953–957.
35. Bernhard JC, Pantuck AJ, Wallerand H, Crepel M, Ferriere JM, Bellec L,
Maurice-Tison S, Robert G, Albouy B, Pasticier G, Soulie M, Lopes D, Lacroix
B, Bensalah K, Pfister C, Thuret R, Tostain J, De La Taille A, Salomon L, Abbou
C, Colombel M, Belldegrun AS, Patard JJ: Predictive factors for ipsilateral
recurrence after nephron-sparing surgery in renal cell carcinoma. Eur Urol
2010, 57:1080–1086.
36. Duvdevani M, Mor Y, Kastin A, Laufer M, Nadu A, Golomb J, Zilberman D,
Nativ O, Ramon J: Renal artery occlusion during nephron-sparing surgery:
retrospective review of 301 cases. Urology 2006, 68:960–963.
37. Duvdevani M, Laufer M, Kastin A, Mor Y, Nadu A, Hanani J, Nativ O, Ramon
J: Is frozen section analysis in nephron sparing surgery necessary? A
clinicopathological study of 301 cases. J Urol 2005, 173:385–387.
38. Gill IS, Matin SF, Desai MM, Kaouk JH, Steinberg A, Mascha E, Thornton J,
Sherief MH, Strzempkowski B, Novick AC: Comparative analysis of
laparoscopic versus open partial nephrectomy for renal tumors in 200
patients. J Urol 2003, 170:64–68.
39. Lifshitz DA, Shikanov SA, Deklaj T, Katz MH, Zorn KC, Eggener SE, Shalhav
AL: Laparoscopic partial nephrectomy: a single-center evolving experi-
ence. Urology 2010, 75:282–287.
40. Porpiglia F, Fiori C, Terrone C, Bollito E, Fontana D, Scarpa RM: Assessment
of surgical margins in renal cell carcinoma after nephron sparing: a
comparative study: laparoscopy vs open surgery. J Urol 2005, 173:1098–1101.
41. Permpongkosol S, Colombo JR Jr, Gill IS, Kavoussi LR: Positive surgical
parenchymal margin after laparoscopic partial nephrectomy for renal
cell carcinoma: oncological outcomes. J Urol 2006, 176:2401–2404.
42. Link RE, Bhayani SB, Allaf ME, Varkarakis I, Inagaki T, Rogers C, Su LM, Jarrett
TW, Kavoussi LR: Exploring the learning curve, pathological outcomes
and perioperative morbidity of laparoscopic partial nephrectomy
performed for renal mass. J Urol 2005, 173:1690–1694.
43. Porpiglia F, Fiori C, Bertolo R, Scarpa RM: Does tumour size really affect the
safety of laparoscopic partial nephrectomy? BJU Int 2011, 108:268–273.
44. Breda A, Stepanian SV, Liao J, Lam JS, Guazzoni G, Stifelman M, Perry K,
Celia A, Breda G, Fornara P, Jackman S, Rosales A, Palou J, Grasso M,
Pansadoro V, Disanto V, Porpiglia F, Milani C, Abbou C, Gaston R, Janetschek
G, Soomro NA, de la Rosette J, Laguna MP, Schulam PG: Positive margins
in laparoscopic partial nephrectomy in 855 cases: a multi-institutional
survey from the United States and Europe. J Urol 2007, 178:47–50.
45. Frank I, Colombo JR Jr, Rubinstein M, Desai M, Kaouk J, Gill IS: Laparoscopic
partial nephrectomy for centrally located renal tumors. J Urol 2006,
175:849–852.
46. Venkatesh R, Weld K, Ames CD, Figenshau SR, Sundaram CP, Andriole GL,
Clayman RV, Landman J: Laparoscopic partial nephrectomy for renal
masses: effect of tumor location. Urology 2006, 67:1169–1174.
47. Scoll BJ, Uzzo RG, Chen DY, Boorjian SA, Kutikov A, Manley BJ, Viterbo R:
Robot-assisted partial nephrectomy: a large single-institutional experi-
ence. Urology 2010, 75:1328–1334.
48. Benway BM, Bhayani SB, Rogers CG, Porter JR, Buffi NM, Figenshau RS,
Mottrie A: Robot-assisted partial nephrectomy: an international
experience. Eur Urol 2010, 57:815–820.
49. Benway BM, Bhayani SB, Rogers CG, Dulabon LM, Patel MN, Lipkin M, Wang
AJ, Stifelman MD: Robot assisted partial nephrectomy versus laparoscopic
partial nephrectomy for renal tumors: a multi-institutional analysis of
perioperative outcomes. J Urol 2009, 182:866–872.
50. Mellon MJ, Lucas SM, Kum JB, Cheng L, Sundaram C: A comparison of
pathologic outcomes of matched robotic and open partial
nephrectomies. Int Urol Nephrol 2013, 45:381–385.
51. Verze P, Fusco F, Minervini A, Antonelli A, Bianchi G, Bocciardi A, Cosciani
Cunico S, Ficarra V, Fiori C, Giancane S, Longo N, Martorana G, Novara G,
Porpiglia F, Rocco F, Rovereto B, Schiavina R, Serni S, Simeone C, Volpe A,
Carini M: Simple enucleation versus standard partial nephrectomy for
clinical T1 renal tumors: Intraoperative, early post-operative and patho-
logical outcomes from a prospective multicenter comparative study
(RECORd Project). Eur Urol Suppl 2013, 12:e172.
52. Minervini A, Ficarra V, Rocco F, Antonelli A, Bertini R, Carmignani G,
Cosciani Cunico S, Fontana D, Longo N, Martorana G, Mirone V, Morgia G,
Novara G, Roscigno M, Schiavina R, Serni S, Simeone C, Simonato A,
Siracusano S, Volpe A, Zattoni F, Zucchi A, Carini M: Simple enucleation is
equivalent to traditional partial nephrectomy for renal cell carcinoma:
Steinestel et al. World Journal of Surgical Oncology 2014, 12:252 Page 6 of 6
http://www.wjso.com/content/12/1/252results of a nonrandomized, retrospective, comparative study. J Urol
2011, 185:1604–1610.
53. Saranchuk JW, Touijer AK, Hakimian P, Snyder ME, Russo P: Partial
nephrectomy for patients with a solitary kidney: the Memorial
Sloan-Kettering experience. BJU Int 2004, 94:1323–1328.
54. Lee DJ, Hruby G, Benson MC, McKiernan JM: Renal function and oncologic
outcomes in nephron sparing surgery for renal masses in solitary
kidneys. World J Urol 2011, 29:343–348.
55. Wszolek MF, Kenney PA, Lee Y, Libertino JA: Comparison of hilar clamping
and non-hilar clamping partial nephrectomy for tumours involving a
solitary kidney. BJU Int 2011, 107:1886–1892.
56. Bensalah K, Pantuck AJ, Rioux-Leclercq N, Thuret R, Montorsi F, Karakiewicz PI,
Mottet N, Zini L, Bertini R, Salomon L, Villers A, Soulie M, Bellec L, Rischmann P,
De la Taille A, Avakian R, Crepel M, Ferriere JM, Bernhard JC, Dujardin T, Pouliot
F, Rigaud J, Pfister C, Albouy B, Guy L, Joniau S, van Poppel H, Lebret T, Culty T,
Saint F: Positive surgical margin appears to have negligible impact on
survival of renal cell carcinomas treated by nephron-sparing surgery.
Eur Urol 2010, 57(3):466–471.
57. Yossepowitch O, Thompson RH, Leibovich BC, Eggener SE, Pettus JA, Kwon ED,
Herr HW, Blute ML, Russo P: Positive surgical margins at partial
nephrectomy: predictors and oncological outcomes. J Urol 2008,
179:2158–2163.
58. Raz O, Mendlovic S, Shilo Y, Leibovici D, Sandbank J, Lindner A, Zisman A:
Positive surgical margins with renal cell carcinoma have a limited
influence on long-term oncological outcomes of nephron sparing
surgery. Urology 2010, 75:277–280.
59. Ani I, Finelli A, Alibhai SM, Timilshina N, Fleshner N, Abouassaly R:
Prevalence and impact on survival of positive surgical margins in partial
nephrectomy for renal cell carcinoma: a population-based study. BJU Int
2013, 111:E300–E305.
60. Venigalla S, Wu G, Miyamoto H: The impact of frozen section analysis
during partial nephrectomy on surgical margin status and tumor
recurrence: a clinicopathologic study of 433 cases. Clin Genitourin Cancer
2013, 11:527–536.
61. Timsit MO, Bazin JP, Thiounn N, Fontaine E, Chretien Y, Dufour B, Mejean A:
Prospective study of safety margins in partial nephrectomy:
intraoperative assessment and contribution of frozen sections
[abstract 638]. Eur Urol Suppl 2006, 5:182.
62. Palermo SM, Dechet C, Trenti E, Mian C, Lodde M, Comploj E, Mazzoleni G,
Hanspeter E, Ambrosini Spaltro A, Mayr R, Pycha A: Cytology as an
alternative to frozen section at the time of nephron-sparing surgery to
evaluate surgical margin status. Urology 2013, 82:1071–1075.
63. Sterious SN, Simhan J, Smaldone MC, Tsai KJ, Canter D, Wameedh E, Li T,
Helstrom J, Viterbo R, Chen DY, Greenberg RE, Kutikov A, Al-Saleem T: Is
there a benefit to frozen section analysis at the time of partial
nephrectomy? Can J Urol 2013, 20:6778–6784.
64. Hillyer SP, Yakoubi R, Autorino R, Isac W, Miocinovic R, Laydner H, Khalifeh A,
Stein RJ, Haber GP, Kaouk JH: Utility of intraoperative frozen section during
robot-assisted partial nephrectomy: a single institution experience.
J Endourol 2013, 27:324–327.
65. Hagemann IS, Lewis JS Jr: A retrospective comparison of 2 methods of
intraoperative margin evaluation during partial nephrectomy. J Urol
2009, 181:500–505.
66. Khalifeh A, Kaouk JH, Bhayani S, Rogers C, Stifelman M, Tanagho YS,
Kumar R, Gorin MA, Sivarajan G, Samarasekera D, Allaf ME: Positive surgical
margins in robot-assisted partial nephrectomy: a multi-institutional
analysis of oncologic outcomes (leave no tumor behind). J Urol 2013,
190:1674–1679.
67. Haferkamp A, Kurosch M, Pritsch M, Hatiboglu G, Macher-Goeppinger S,
Pfitzenmaier J, Pahernik S, Wagener N, Hohenfellner M: Prognostic factorsinfluencing long-term survival of patients undergoing nephron-sparing
surgery for nonmetastatic renal-cell carcinoma (RCC) with imperative
indications. Ann Surg Oncol 2010, 17:544–551.
68. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H: An outcome
prediction model for patients with clear cell renal cell carcinoma treated
with radical nephrectomy based on tumor stage, size, grade and
necrosis: the sign score. J Urol 2002, 168:2395–2400.
69. Sundaram V, Figenshau RS, Roytman TM, Kibel AS, Grubb RL 3rd, Bullock A,
Benway BM, Bhayani SB: Positive margin during partial nephrectomy:
does cancer remain in the renal remnant? Urology 2011, 77:1400–1403.
70. Ray ER, Turney BW, Singh R, Chandra A, Cranston DW, O'Brien TS: Open
partial nephrectomy: outcomes from two UK centres. BJU Int 2006,
97:1211–1215.
doi:10.1186/1477-7819-12-252
Cite this article as: Steinestel et al.: Positive surgical margins in nephron-
sparing surgery: risk factors and therapeutic consequences. World Journal
of Surgical Oncology 2014 12:252.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
